Operating a pharmaceutical establishment in South Africa requires disciplined quality systems, evidence-based compliance, and documentation that withstands SAHPRA’s GMP and GDP scrutiny.
GH Strategies partners with pharmaceutical manufacturers, importers, exporters, and distributors to develop licensing submissions that are technically robust, strategically positioned, and fully aligned with Section 22C(1)(b) requirements.
What GH Strategies Delivers
Licensing Strategy Grounded in GMP Principles
We interpret SAHPRA’s Section 22C(1)(b) expectations and design a licensing pathway rooted in quality, documentation integrity, and operational readiness – not box-ticking.
Pharmaceutical Establishment Licence Application Architecture
Your submission is structured with regulatory clarity, controlled documentation, and GMP-aligned evidence that supports all declared activities.
Quality Management System Alignment for Licence Approval
We assess and elevate QMS elements – from SOP frameworks to deviation systems – ensuring they meet WHO GMP and SAHPRA GDP standards.
Facility & Operational Compliance Intelligence
We evaluate material flow, personnel flow, storage controls, environmental conditions, and risk points to ensure facility design supports compliance.
Regulatory Liaison & Licensing Communication
GH Strategies manages communication with SAHPRA, ensuring your application remains aligned, complete, and responsive throughout the review cycle.
Post-Licence Support & Compliance Continuity
Beyond approval, we strengthen your operation with QMS updates, GMP risk mitigation, and regulatory intelligence that minimises the chance of future conditions or findings.
Planning to manufacture, import, or distribute medicines in South Africa?
Speak to an Expert.
Four Pillars of a SAHPRA-Ready Pharmaceutical Establishment
SAHPRA expects proof that your manufacturing, packaging, testing, or importing operations follow Good Manufacturing Practice, including documented controls, traceability, and quality oversight
Wholesalers and distribution partners must demonstrate Good Distribution Practice across warehousing, cold chain, transport, and temperature-controlled environments
A robust QMS – including SOPs, change control, deviations, CAPA, training, vendor qualification, and internal audits – forms the backbone of any successful licensing submission
SAHPRA expects clear accountability. Your RP and supporting team must demonstrate qualifications, defined roles, and competency aligned with pharmaceutical regulatory standards.
Strategic Value of a SAHPRA Pharmaceutical Establishment Licence
A SAHPRA Pharmaceutical Establishment Licence is not merely a regulatory requirement, it is a credibility marker.
It demonstrates GMP/GDP maturity, accelerates future product registrations, enables compliant market operations, strengthens supply chain reliability, enhances trust with partners and regulators, and underpins sustainable market expansion.
A strong licence signals that the organisation operates with discipline, traceability, and regulatory integrity
Frequently Asked Questions (FAQs)
Manufacturing, packaging, testing, importing, exporting, warehousing, distribution, and wholesaling of medicines.
Yes. SAHPRA conducts GMP or GWP inspections to confirm documentation accuracy and operational control.
Yes, we diagnose gaps, rebuild documentation, strengthen QMS evidence, and prepare a structured resubmission.
Deviation management, CAPA effectiveness, change control, training records, supplier qualification, and environmental monitoring.
Yes – and doing so helps ensure layout and flows meet GMP expectations before installation or commissioning.
Yes. All pharmaceutical establishments must appoint a SAPC registered RP with defined regulatory responsibilities.
Let’s Build Something That Lasts
Strengthen your trajectory with a GMP/GDP licensing readiness assessment before applying to SAHPRA.